anti-Vestigial Like 4 (Drosophila) (VGLL4) Antibodies

Human Vestigial Like 4 (Drosophila) (VGLL4) interaction partners

1. Data report that VGLL4 functions as a suppressor of breast tumor (BC) growth and progression. Its low expression correlated with a poor prognosis. Its ectopic expression in BC cell lines reduced cell proliferation, migration, and tumor formation in xenograft mouse model. VGLL4 interacts with TEAD1 via its second TEAD-interacting domain, antagonizing YAP-dependent tumor growth.

2. Hippo pathway transcription factor TEAD4 directly associates with the Wnt pathway transcription factor TCF4 via their DNA-binding domains, forming a complex on target genes. VGLL4 binds to this TEAD4-TCF4 complex to inhibit transactivation of both TCF4 and TEAD4.

3. Results identify VGLL4 as a direct target gene of miR-130b in Bladder cancer (BCa) cells. Its suppression is crucial for miR-130b-induced BCa cell proliferation, migration and invasion.

4. The Vgll4 is phosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug-induced mitotic arrest and also in normal mitosis.

5. VGLL4 - novel candidate genes validated in a large case-control sample of schizophrenia.

6. The expression level of VGLL4 protein was down-regulated in gastric cancer tissues.VGLL4 inhibits epithelial-mesenchymal transition in part through suppressing Wnt-beta-catenin signaling pathway in gastric cancer.

7. our study suggested that downregulation of VGLL4 was very important in the progression of ESCC, and restoring the function of VGLL4 might be a promising therapeutic strategy for ESCC.

8. VGLL4 directly competes with YAP in binding to TEADs and executes its growth-inhibitory function through two TDU domains.

9. rs2616551 in VGLL4 was found to be nominally associated with anorexia nervosa.

10. This study introduces a novel gain-of-function approach for studying hESC maintenance and presents VGLL4 as a previously undescribed regulator of this process.

11. Loss of VGLL4 expression is associated with gastric cancer.

12. Vgl-4 may play a role in the apoptotic pathways by regulating translocation of IAPs between different cell compartments.

13. IRF2BP2 was identifies as a novel VGLL4 partner.

14. This gene is named Vestigial-like 4, to distinguish it from 3 previously described genes Vgl-1, Vgl-2 and Vgl-3. Contains 2 motifs, found in the Drosophila transcription cofactor Vestigial, that interact with the TEF-1 family of transcription factors.

Mouse (Murine) Vestigial Like 4 (Drosophila) (VGLL4) interaction partners

1. VGLL4 acted as an adaptor protein that enhanced the interaction between TEAD4 and CtBP2, and this TEAD4-VGLL4-CtBP2 ternary complex dynamically existed at the early stage of adipogenesis.

2. Results revealed an essential role of VGLL4 in heart valve morphogenesis via regulating valvar interstitial cells proliferation and apoptosis. Furthermore, its deletion resulted in progressive valve disease. These findings suggest that mutations in VGLL4 may underlie human congenital heart valve dysplasia.

3. Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma in a mouse model with G2/M phase arrest and apoptosis promotion.

4. VGLL4 inhibits cardiomyocyte proliferation by inhibiting TEAD1-YAP interaction and by targeting TEAD1 for degradation.

5. Vgl-4 modulates the activity of TEF-1 factors and counteracts alpha1-adrenergic activation of gene expression in cardiac myocytes